Symbols / DCTH Stock $10.64 -4.92% Delcath Systems, Inc.
DCTH (Stock) Chart
About
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.
Stock Fundamentals
Scroll to Statements| Market Cap | 369.70M | Enterprise Value | 298.71M | Income | 2.70M | Sales | 85.23M | Book/sh | 3.21 | Cash/sh | 2.62 |
| Dividend Yield | — | Payout | 0.00% | Employees | 156 | IPO | — | P/E | 152.00 | Forward P/E | -54.29 |
| PEG | 1.60 | P/S | 4.34 | P/B | 3.32 | P/C | — | EV/EBITDA | 332.64 | EV/Sales | 3.50 |
| Quick Ratio | 9.43 | Current Ratio | 10.92 | Debt/Eq | 0.84 | LT Debt/Eq | — | EPS (ttm) | 0.07 | EPS next Y | -0.20 |
| EPS Growth | — | Revenue Growth | 37.30% | Earnings | 2026-05-07 | ROA | 0.41% | ROE | 3.00% | ROIC | — |
| Gross Margin | 86.16% | Oper. Margin | -10.54% | Profit Margin | 3.17% | Shs Outstand | 34.45M | Shs Float | 28.60M | Short Float | 12.54% |
| Short Ratio | 10.78 | Short Interest | — | 52W High | 18.23 | 52W Low | 8.12 | Beta | 0.43 | Avg Volume | 421.51K |
| Volume | 271.33K | Target Price | $21.33 | Recom | Strong_buy | Prev Close | $11.19 | Price | $10.64 | Change | -4.92% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-26 | main | BTIG | Buy → Buy | $19 |
| 2026-01-09 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2025-11-05 | main | Stephens & Co. | Overweight → Overweight | $18 |
| 2025-11-04 | reit | BTIG | Buy → Buy | $23 |
| 2025-10-21 | main | Canaccord Genuity | Buy → Buy | $21 |
| 2025-10-20 | main | HC Wainwright & Co. | Buy → Buy | $30 |
| 2025-08-07 | main | HC Wainwright & Co. | Buy → Buy | $31 |
| 2025-06-23 | reit | Stephens & Co. | Overweight → Overweight | $25 |
| 2025-05-23 | main | HC Wainwright & Co. | Buy → Buy | $29 |
| 2025-03-07 | main | HC Wainwright & Co. | Buy → Buy | $24 |
| 2025-01-17 | main | Craig-Hallum | Buy → Buy | $21 |
| 2025-01-14 | reit | HC Wainwright & Co. | Buy → Buy | $22 |
| 2024-11-11 | reit | HC Wainwright & Co. | Buy → Buy | $22 |
| 2024-08-06 | reit | Stephens & Co. | Overweight → Overweight | $25 |
| 2024-08-06 | reit | HC Wainwright & Co. | Buy → Buy | $22 |
| 2024-06-28 | init | Craig-Hallum | — → Buy | $18 |
| 2024-05-15 | main | HC Wainwright & Co. | Buy → Buy | $22 |
| 2024-05-14 | init | Stephens & Co. | — → Overweight | $25 |
| 2024-03-27 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2023-09-07 | main | Canaccord Genuity | Buy → Buy | $21 |
- Delcath Systems will discuss Q1 results on a May 7 morning call - Stock Titan hu, 23 Apr 2026 12
- Delcath Systems (NASDAQ:DCTH) Stock Price Up 0.3% - Time to Buy? - MarketBeat Sat, 18 Apr 2026 05
- DELCATH SYSTEMS ($DCTH) Releases Q4 2025 Earnings - Quiver Quantitative hu, 26 Feb 2026 08
- Delcath (DCTH) Stock Adds to Position (-1.46%) 2026-04-16 - Asset Allocation - Cổng thông tin điện tử Tỉnh Sơn La Fri, 17 Apr 2026 00
- Implied Volatility Surging for Delcath Systems Stock Options - Yahoo Finance ue, 07 Apr 2026 07
- Delcath: Fundamentals Intact, Despite Share Price Weakness (NASDAQ:DCTH) - Seeking Alpha Mon, 02 Mar 2026 08
- Is Delcath (DCTH) Stock Discounted Now | Price at $10.18, Up 1.34% - Bearish Pattern - UBND thành phố Hải Phòng Mon, 13 Apr 2026 07
- Why We're Not Concerned Yet About Delcath Systems, Inc.'s (NASDAQ:DCTH) 28% Share Price Plunge - simplywall.st Fri, 21 Nov 2025 08
- Delcath Systems, Inc. (DCTH) Stock Analysis: Exploring a Potential 134% Upside in the Healthcare Sector - DirectorsTalk Interviews Fri, 20 Feb 2026 08
- Delcath Systems, Inc. (NASDAQ:DCTH) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat ue, 21 Apr 2026 12
- DCTH SEC Filings - Delcath Sys 10-K, 10-Q, 8-K Forms - Stock Titan Sat, 11 Apr 2026 03
- Delcath Systems: Stabilizing Fundamentals Justify A Rating Upgrade (NASDAQ:DCTH) - Seeking Alpha ue, 13 Jan 2026 08
- JPMorgan Chase & Co. Decreases Position in Delcath Systems, Inc. $DCTH - MarketBeat Sun, 19 Apr 2026 08
- European cancer guidelines add Delcath liver therapy for eye melanoma - Stock Titan Mon, 06 Apr 2026 07
- Three doctors to present Delcath liver cancer therapy data at SIR 2026 - Stock Titan Wed, 01 Apr 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
85.23
+129.08%
|
37.20
+1701.69%
|
2.06
-24.05%
|
2.72
|
| Operating Revenue |
|
85.23
+129.08%
|
37.20
+1701.69%
|
2.06
-18.96%
|
2.55
|
| Cost Of Revenue |
|
11.80
+90.64%
|
6.19
+874.49%
|
0.64
-7.43%
|
0.69
|
| Reconciled Cost Of Revenue |
|
11.80
+90.64%
|
6.19
+874.49%
|
0.64
-7.43%
|
0.69
|
| Gross Profit |
|
73.43
+136.75%
|
31.02
+2069.02%
|
1.43
-29.66%
|
2.03
|
| Operating Expense |
|
72.77
+67.58%
|
43.43
+9.63%
|
39.61
+10.38%
|
35.89
|
| Research And Development |
|
29.25
+110.80%
|
13.87
-20.73%
|
17.50
-5.82%
|
18.58
|
| Selling General And Administration |
|
43.53
+47.29%
|
29.55
+33.66%
|
22.11
+27.78%
|
17.30
|
| Total Expenses |
|
84.57
+70.45%
|
49.62
+23.28%
|
40.25
+10.05%
|
36.57
|
| Operating Income |
|
0.66
+105.32%
|
-12.41
+67.50%
|
-38.18
-12.79%
|
-33.85
|
| Total Operating Income As Reported |
|
0.66
+105.32%
|
-12.41
+67.50%
|
-38.18
-12.79%
|
-33.85
|
| EBITDA |
|
1.01
+108.28%
|
-12.18
+67.76%
|
-37.78
-12.15%
|
-33.69
|
| Normalized EBITDA |
|
1.01
-46.61%
|
1.89
+106.35%
|
-29.79
+11.59%
|
-33.69
|
| Reconciled Depreciation |
|
0.35
+52.40%
|
0.23
-42.61%
|
0.40
+202.27%
|
0.13
|
| EBIT |
|
0.66
+105.32%
|
-12.41
+67.50%
|
-38.18
-12.89%
|
-33.82
|
| Total Unusual Items |
|
—
|
-14.07
-75.93%
|
-8.00
|
—
|
| Total Unusual Items Excluding Goodwill |
|
—
|
-14.07
-75.93%
|
-8.00
|
—
|
| Net Income |
|
2.70
+110.23%
|
-26.39
+44.66%
|
-47.68
-30.60%
|
-36.51
|
| Pretax Income |
|
3.51
+113.30%
|
-26.39
+44.66%
|
-47.68
-30.60%
|
-36.51
|
| Net Non Operating Interest Income Expense |
|
2.92
+2236.00%
|
0.12
+108.69%
|
-1.44
+46.41%
|
-2.69
|
| Interest Expense Non Operating |
|
—
|
—
|
1.44
-46.41%
|
2.69
|
| Net Interest Income |
|
2.92
+2236.00%
|
0.12
+108.69%
|
-1.44
+46.41%
|
-2.69
|
| Interest Expense |
|
—
|
—
|
1.44
-46.41%
|
2.69
|
| Other Income Expense |
|
-0.07
+99.50%
|
-14.10
-75.02%
|
-8.06
-26956.67%
|
0.03
|
| Other Non Operating Income Expenses |
|
-0.07
-133.33%
|
-0.03
+49.15%
|
-0.06
-296.67%
|
0.03
|
| Gain On Sale Of Security |
|
—
|
-14.07
-75.93%
|
-8.00
|
—
|
| Tax Provision |
|
0.81
|
0.00
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
2.70
+110.23%
|
-26.39
+44.66%
|
-47.68
-30.60%
|
-36.51
|
| Net Income From Continuing Operation Net Minority Interest |
|
2.70
+110.23%
|
-26.39
+44.66%
|
-47.68
-30.60%
|
-36.51
|
| Net Income From Continuing And Discontinued Operation |
|
2.70
+110.23%
|
-26.39
+44.66%
|
-47.68
-30.60%
|
-36.51
|
| Net Income Continuous Operations |
|
2.70
+110.23%
|
-26.39
+44.66%
|
-47.68
-30.60%
|
-36.51
|
| Normalized Income |
|
2.70
+121.92%
|
-12.31
+68.96%
|
-39.68
-8.69%
|
-36.51
|
| Net Income Common Stockholders |
|
2.70
+110.23%
|
-26.39
+44.66%
|
-47.68
-30.60%
|
-36.51
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
—
|
—
|
| Diluted EPS |
|
0.07
+107.53%
|
-0.93
+68.37%
|
-2.94
+28.64%
|
-4.12
|
| Basic EPS |
|
0.08
+108.60%
|
-0.93
+68.37%
|
-2.94
+28.64%
|
-4.12
|
| Basic Average Shares |
|
35.82
+25.64%
|
28.51
+75.67%
|
16.23
+0.00%
|
16.23
|
| Diluted Average Shares |
|
39.92
+40.01%
|
28.51
+75.67%
|
16.23
+0.00%
|
16.23
|
| Diluted NI Availto Com Stockholders |
|
2.70
+110.23%
|
-26.39
+44.66%
|
-47.68
-30.60%
|
-36.51
|
| Total Other Finance Cost |
|
-2.92
-2236.00%
|
-0.12
-108.69%
|
1.44
|
—
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
38.61
|
| Current Assets |
|
37.16
|
| Cash Cash Equivalents And Short Term Investments |
|
32.45
|
| Cash And Cash Equivalents |
|
12.65
|
| Other Short Term Investments |
|
19.81
|
| Receivables |
|
0.48
|
| Accounts Receivable |
|
0.24
|
| Taxes Receivable |
|
0.09
|
| Accrued Interest Receivable |
|
0.15
|
| Inventory |
|
3.32
|
| Raw Materials |
|
1.44
|
| Work In Process |
|
1.75
|
| Finished Goods |
|
0.13
|
| Prepaid Assets |
|
0.51
|
| Restricted Cash |
|
0.05
|
| Other Current Assets |
|
0.34
|
| Total Non Current Assets |
|
1.46
|
| Net PPE |
|
1.46
|
| Gross PPE |
|
6.53
|
| Accumulated Depreciation |
|
-5.08
|
| Properties |
|
0.00
|
| Buildings And Improvements |
|
1.32
|
| Machinery Furniture Equipment |
|
2.06
|
| Construction In Progress |
|
0.00
|
| Other Properties |
|
1.37
|
| Leases |
|
1.79
|
| Total Liabilities Net Minority Interest |
|
22.84
|
| Current Liabilities |
|
16.45
|
| Payables And Accrued Expenses |
|
4.33
|
| Payables |
|
1.01
|
| Accounts Payable |
|
1.01
|
| Current Accrued Expenses |
|
3.31
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
1.93
|
| Current Debt And Capital Lease Obligation |
|
10.19
|
| Current Debt |
|
10.15
|
| Other Current Borrowings |
|
10.15
|
| Current Capital Lease Obligation |
|
0.04
|
| Current Deferred Liabilities |
|
—
|
| Current Deferred Revenue |
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
6.39
|
| Long Term Debt And Capital Lease Obligation |
|
0.00
|
| Long Term Debt |
|
—
|
| Long Term Capital Lease Obligation |
|
0.00
|
| Non Current Deferred Liabilities |
|
—
|
| Non Current Deferred Revenue |
|
—
|
| Other Non Current Liabilities |
|
0.84
|
| Stockholders Equity |
|
15.78
|
| Common Stock Equity |
|
15.78
|
| Capital Stock |
|
0.23
|
| Common Stock |
|
0.23
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
22.76
|
| Ordinary Shares Number |
|
22.76
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
520.58
|
| Retained Earnings |
|
-505.16
|
| Gains Losses Not Affecting Retained Earnings |
|
0.14
|
| Other Equity Adjustments |
|
0.14
|
| Total Equity Gross Minority Interest |
|
15.78
|
| Total Capitalization |
|
15.78
|
| Invested Capital |
|
25.93
|
| Total Debt |
|
10.19
|
| Net Debt |
|
—
|
| Capital Lease Obligations |
|
0.04
|
| Net Tangible Assets |
|
15.78
|
| Tangible Book Value |
|
15.78
|
| Derivative Product Liabilities |
|
5.55
|
| Interest Payable |
|
0.71
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
22.52
+220.53%
|
-18.68
+40.22%
|
-31.25
-25.25%
|
-24.95
|
| Cash Flow From Continuing Operating Activities |
|
22.52
+220.53%
|
-18.68
+40.22%
|
-31.25
-25.25%
|
-24.95
|
| Net Income From Continuing Operations |
|
2.70
+110.23%
|
-26.39
+44.66%
|
-47.68
-30.60%
|
-36.51
|
| Depreciation Amortization Depletion |
|
0.35
+52.40%
|
0.23
-42.61%
|
0.40
+202.27%
|
0.13
|
| Depreciation |
|
0.35
+52.40%
|
0.23
-42.61%
|
0.40
+202.27%
|
0.13
|
| Depreciation And Amortization |
|
0.35
+52.40%
|
0.23
-42.61%
|
0.40
+202.27%
|
0.13
|
| Other Non Cash Items |
|
—
|
0.59
-36.65%
|
0.94
-31.73%
|
1.37
|
| Stock Based Compensation |
|
24.23
+148.10%
|
9.77
+19.83%
|
8.15
+2.64%
|
7.94
|
| Operating Gains Losses |
|
—
|
14.07
+75.93%
|
8.00
|
—
|
| Gain Loss On Investment Securities |
|
—
|
14.07
+75.93%
|
8.00
|
—
|
| Change In Working Capital |
|
-3.07
+80.23%
|
-15.52
-1613.13%
|
-0.91
-142.86%
|
2.11
|
| Change In Receivables |
|
-0.85
+91.98%
|
-10.65
-8619.20%
|
0.12
+138.82%
|
-0.32
|
| Changes In Account Receivables |
|
-0.85
+91.98%
|
-10.65
-8619.20%
|
0.12
+138.82%
|
-0.32
|
| Change In Inventory |
|
-3.32
+8.09%
|
-3.61
-172.73%
|
-1.32
-125.55%
|
-0.59
|
| Change In Prepaid Assets |
|
-3.42
-108.72%
|
-1.64
-259.28%
|
1.03
+32.95%
|
0.77
|
| Change In Payables And Accrued Expense |
|
4.77
+894.99%
|
0.48
+340.70%
|
-0.20
-111.07%
|
1.80
|
| Change In Accrued Expense |
|
—
|
—
|
—
|
—
|
| Change In Payable |
|
4.77
+894.99%
|
0.48
+340.70%
|
-0.20
|
—
|
| Change In Account Payable |
|
4.77
+894.99%
|
0.48
+340.70%
|
-0.20
|
—
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
-0.17
|
| Change In Other Current Liabilities |
|
-0.24
-138.61%
|
-0.10
+81.19%
|
-0.54
-186.47%
|
0.62
|
| Investing Cash Flow |
|
-26.59
-2610.50%
|
-0.98
+95.02%
|
-19.71
-9330.14%
|
-0.21
|
| Cash Flow From Continuing Investing Activities |
|
-26.59
-2610.50%
|
-0.98
+95.02%
|
-19.71
-9330.14%
|
-0.21
|
| Net PPE Purchase And Sale |
|
-1.55
-176.74%
|
-0.56
-863.79%
|
-0.06
+72.25%
|
-0.21
|
| Purchase Of PPE |
|
-1.55
-176.74%
|
-0.56
-863.79%
|
-0.06
+72.25%
|
-0.21
|
| Capital Expenditure |
|
-1.55
-176.74%
|
-0.56
-863.79%
|
-0.06
+72.25%
|
-0.21
|
| Net Investment Purchase And Sale |
|
-25.04
-5834.36%
|
-0.42
+97.85%
|
-19.65
|
0.00
|
| Purchase Of Investment |
|
-93.22
-77.71%
|
-52.45
-166.92%
|
-19.65
|
0.00
|
| Sale Of Investment |
|
68.17
+31.02%
|
52.03
|
0.00
|
0.00
|
| Financing Cash Flow |
|
15.05
-61.82%
|
39.41
-23.89%
|
51.78
+410.48%
|
10.14
|
| Cash Flow From Continuing Financing Activities |
|
15.05
-61.82%
|
39.41
-23.89%
|
51.78
+410.48%
|
10.14
|
| Net Issuance Payments Of Debt |
|
0.00
+100.00%
|
-10.61
-68.07%
|
-6.31
-784.17%
|
-0.71
|
| Issuance Of Debt |
|
—
|
—
|
—
|
0.00
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-10.61
-68.07%
|
-6.31
-784.17%
|
-0.71
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Payments |
|
0.00
+100.00%
|
-10.61
-68.07%
|
-6.31
-784.17%
|
-0.71
|
| Net Long Term Debt Issuance |
|
0.00
+100.00%
|
-10.61
-68.07%
|
-6.31
-784.17%
|
-0.71
|
| Net Common Stock Issuance |
|
-5.52
-178.61%
|
7.02
-69.58%
|
23.08
+112.61%
|
10.86
|
| Common Stock Payments |
|
-6.00
|
0.00
|
—
|
—
|
| Repurchase Of Capital Stock |
|
-6.00
|
0.00
|
—
|
—
|
| Proceeds From Stock Option Exercised |
|
20.57
-52.17%
|
43.00
+22.83%
|
35.01
|
0.00
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
—
|
| Changes In Cash |
|
10.97
-44.43%
|
19.75
+2314.18%
|
0.82
+105.45%
|
-15.02
|
| Effect Of Exchange Rate Changes |
|
0.07
+312.50%
|
-0.03
-157.14%
|
0.06
+148.70%
|
-0.12
|
| Beginning Cash Position |
|
32.41
+155.29%
|
12.70
+7.39%
|
11.82
-56.14%
|
26.95
|
| End Cash Position |
|
43.45
+34.07%
|
32.41
+155.29%
|
12.70
+7.39%
|
11.82
|
| Free Cash Flow |
|
20.97
+208.99%
|
-19.24
+38.55%
|
-31.31
-24.44%
|
-25.16
|
| Interest Paid Supplemental Data |
|
0.00
-100.00%
|
1.24
-15.28%
|
1.46
-22.10%
|
1.87
|
| Income Tax Paid Supplemental Data |
|
1.54
|
0.00
|
—
|
—
|
| Amortization Of Securities |
|
-1.70
-188.93%
|
-0.59
-288.74%
|
-0.15
|
0.00
|
| Common Stock Issuance |
|
0.48
-93.15%
|
7.02
-69.58%
|
23.08
+112.61%
|
10.86
|
| Interest Paid CFO |
|
0.00
+100.00%
|
-0.85
|
0.00
|
—
|
| Issuance Of Capital Stock |
|
0.48
-93.15%
|
7.02
-69.58%
|
23.08
+112.61%
|
10.86
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-03-06 View
- 8-K2026-03-03 View
- 42026-03-03 View
- 10-K2026-02-26 View
- 8-K2026-02-26 View
- 42026-02-18 View
- 42026-02-18 View
- 42026-02-18 View
- 42026-02-18 View
- 42026-02-18 View
- 42026-02-18 View
- 8-K2026-01-12 View
- 42025-11-25 View
- 8-K2025-11-20 View
- 42025-11-13 View
- 10-Q2025-11-04 View
- 8-K2025-11-04 View
- 8-K2025-10-20 View
- 8-K2025-08-15 View
- 10-Q2025-08-06 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|